RadNet (RDNT) Projected to Announce Earnings on Sunday

RadNet (NASDAQ:RDNT) is anticipated to post its Q3 2026 results before the market opens on Sunday, November 8th. Analysts expect the company to announce earnings of $0.2214 per share and revenue of $639.97 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Monday, November 9, 2026 at 10:30 AM ET.

RadNet (NASDAQ:RDNT) last announced its quarterly earnings results on Monday, August 10th. The medical research company reported $0.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.20 by $0.09. RadNet had a negative net margin of 0.93% and a positive return on equity of 2.61%. The business had revenue of $622.72 million during the quarter, compared to the consensus estimate of $610.87 million. During the same quarter last year, the firm posted $0.31 EPS. The business’s revenue was up 25.0% compared to the same quarter last year. On average, analysts expect RadNet to post $0.49 EPS for the current fiscal year and $0.87 EPS for the next fiscal year.

RadNet Stock Down 0.2%

Shares of NASDAQ RDNT opened at $73.49 on Friday. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.94. RadNet has a 52 week low of $50.82 and a 52 week high of $85.84. The firm has a 50-day moving average price of $72.56 and a 200 day moving average price of $65.30. The stock has a market capitalization of $5.78 billion, a price-to-earnings ratio of -272.18 and a beta of 1.41.

Wall Street Analysts Forecast Growth

RDNT has been the topic of several recent analyst reports. Raymond James Financial restated a “strong-buy” rating on shares of RadNet in a research report on Tuesday, September 22nd. Truist Financial lifted their price target on shares of RadNet from $90.00 to $94.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. Jefferies Financial Group reissued a “buy” rating on shares of RadNet in a research note on Friday, July 31st. Barclays upped their price target on RadNet from $65.00 to $79.00 and gave the stock an “overweight” rating in a report on Friday, August 28th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of RadNet in a report on Friday, August 7th. Three equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $90.00.

About RadNet

RadNet, Inc (NASDAQ: RDNT) is an outpatient diagnostic imaging company that operates imaging centers and provides related healthcare services. Its facilities offer diagnostic radiology and imaging procedures used to help detect, diagnose, and monitor medical conditions.

The company’s services generally include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), mammography, ultrasound, X-ray, and other imaging procedures. RadNet also provides image-guided and interventional radiology services in selected markets, along with digital imaging, radiology, and information-technology solutions.

Founded in 1981, RadNet serves patients, physicians, hospitals, and other healthcare organizations through a network of outpatient imaging centers primarily located in the United States, including markets in California, New York, New Jersey, Maryland, and Delaware.